Previous 10 | Next 10 |
Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference PR Newswire CARLSBAD, Calif. , Nov. 8, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation pre...
2023-11-08 10:15:36 ET More on Tyra Biosciences Tyra Biosciences: FDA ODD Designation Progresses TYRA-300 Seeking Alpha’s Quant Rating on Tyra Biosciences Historical earnings data for Tyra Biosciences Financial information for Tyra Biosciences ...
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights PR Newswire - Enrollment and dose escalation ongoing in SURF301 Phase 1/2 oncology - - Presented additional preclinical data on TYRA-300 in achondroplasia at ASBMR and ASHG - - First patie...
Tyra Biosciences Inc. (TYRA) is expected to report $-0.35 for Q3 2023
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia at the ASBMR and ASHG 2023 Annual Meetings PR Newswire CARLSBAD, Calif. , Sept. 21, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company foc...
Tyra Biosciences to Participate at 2023 Cantor Global Healthcare Conference PR Newswire CARLSBAD, Calif. , Sept. 12, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision...
2023-08-29 18:30:23 ET Summary Tyra's net loss continues to improve in Q2 2023. TYRA-300 has been granted Orphan Drug Designation status by the FDA recently, continuing its progression to market. Tyra's substantial cash reserves and ongoing trials support the development of it...
2023-08-11 16:23:04 ET More on Tyra Biosciences Tyra Biosciences: Early Stage Developer Of Novel FGFR3-Selective Molecules Tyra Biosciences gets FDA orphan drug designation for dwarfism therapy Tyra Biosciences soars over 50% on public debut Precision oncolog...
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights PR Newswire -Orphan Drug Designation granted to TYRA-300 for achondroplasia- - SURF301 Phase 1/2 oncology study remains on target; enrollment ongoing in Part B - -TYRA-200 Phase 1 study o...
2023-08-01 10:23:02 ET Tyra Biosciences ( NASDAQ: TYRA ) said that the US Food and Drug Administration has granted orphan drug status to its lead drug candidate TYRA-300 in the treatment of achondroplasia, the most common form of dwarfism. The biotech company said it is prepar...
News, Short Squeeze, Breakout and More Instantly...
Tyra Biosciences Inc. Company Name:
TYRA Stock Symbol:
OTCMKTS Market:
Tyra Biosciences Inc. Website:
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights PR Newswire - TYRA-300 on track in ACH and oncology; SURF301 Ph1 initial results and ACH IND submission expected in 2H24 - - Cash, cash equivalents, and marketable securities of $382.5 milli...
Tyra Biosciences Announces Appointments of Susan Moran, M.D., M.S.C.E. and S. Michael Rothenberg, M.D., Ph.D. to its Board of Directors PR Newswire CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnolog...
NEW YORK, NY / ACCESSWIRE / April 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyra Biosciences Inc ("Tyra" or "the Company") (NASDAQ:TYRA). Investors who purchased Tyra securities are encouraged to obtain additional information an...